Bevacizumab vs Ranibizumab: Cost-Effectiveness for AMDBevacizumab vs Ranibizumab: Cost-Effectiveness for AMD
Bevacizumab is more cost-effective than ranibizumab for the treatment of newly diagnosed neovascular macular degeneration, according to a mathematical model. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 14, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Cerulean starts dosing in phase 2 combination therapy trial for ovarian cancer treatment
US-based Cerulean Pharma has dosed the first patient in a phase 2 clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) for the treatment of relapsed ovarian cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 12, 2014 Category: Pharmaceuticals Source Type: news

Roche delivers strong 2013 results
Group sales rise 6% to 46.8 billion Swiss francs; Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin, MabThera/Rituxan, Actemra/RoActemra and Lucentis. Diagnostics sales up 4% on strong Professional Diagnostics performance (Source: Roche Investor Update)
Source: Roche Investor Update - January 30, 2014 Category: Pharmaceuticals Source Type: news

Bev Good Option for Elderly mCRC Patients?Bev Good Option for Elderly mCRC Patients?
Bevacizumab may prove a strong -- and tolerable -- therapeutic option for elderly patients with unresectable, metastatic colorectal cancer, according to a study reviewed by Dr. Alok Khorana. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 28, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

New Regimen for Elderly Patients With mCRCNew Regimen for Elderly Patients With mCRC
Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer. Medscape Oncology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 17, 2014 Category: Gastroenterology Tags: Hematology-Oncology Commentary Source Type: news

Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(University of Colorado Denver) Addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The two- and three- year overall survival rates were 89.8 percent and 80.2 percent, respectively. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 15, 2014 Category: Biology Source Type: news

Adding drug to standard chemo shows promise for women with triple-negative breast cancer
In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators reported at the 2013 San Antonio Breast Cancer Symposium.The results are especially promising in the case of carboplatin, study leaders say, as Avastin has shown little effectiveness as a long-term preventer of cancer recurrence. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Breast Cancer: Adding Avastin Boosts Toxicity (CME/CE)
SAN ANTONIO (MedPage Today) -- Beleaguered bevacizumab (Avastin) has failed another test in breast cancer, a researcher said here. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 16, 2013 Category: Hematology Source Type: news

Carboplatin for Triple-Negative Breast CancerCarboplatin for Triple-Negative Breast Cancer
Adding carboplatin or bevacizumab to standard neoadjuvant chemotherapy for triple-negative breast cancer improves pathologic complete response, but bevacizumab toxicity is too high. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New presurgery treatment combination more effective for women with triple-negative breast cancer
(American Association for Cancer Research) Adding the chemotherapy drug carboplatin and/or the antibody therapy bevacizumab to standard presurgery chemotherapy increased the number of women with triple-negative breast cancer who had no residual cancer detected at surgery, according to results of a randomized, phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2013 Category: Cancer & Oncology Source Type: news

Additional drug shows promise for women with triple-negative breast cancer
(Dana-Farber Cancer Institute) In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators will report at the 2013 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 13, 2013 Category: Global & Universal Source Type: news

Bevacizumab Bombs Again in the BETH Breast Cancer StudyBevacizumab Bombs Again in the BETH Breast Cancer Study
With 2 different chemotherapy regimens, the addition of bevacizumab added no benefit and more adverse events. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Avastin Misses Mark Again in Breast Cancer (CME/CE)
SAN ANTONIO (MedPage Today) -- The addition of bevacizumab (Avastin) to standard adjuvant therapy for HER2-positive breast cancer failed to improve invasive disease-free survival in a randomized clinical trial. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2013 Category: Hematology Source Type: news

Four-drug regimen shows first-line efficacy in advanced NSCLC
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - December 2, 2013 Category: Cancer & Oncology Source Type: news

Four-drug regimen shows first-line efficacy in advanced NSCLC
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 2, 2013 Category: Cancer & Oncology Source Type: news

Is it time to call a truce in the 'battle against disease'? | Kostas Kostarelos
Our obsession with war-like language in medicine and medical research may unconsciously limit our creativity in tackling diseaseAlmost every night I have watched the news these past few months my senses have been assaulted by unpleasant, at times distressing, images of war: missiles, killings and chemical bombs in Syria, Kenya, the USA. I wake up the next morning, pretending or forgetting what I watched the night before, and going to work with our researchers to develop the next potential high-tech cure for cancer, thinking: "does what we do matter at all … ?"So I was intrigued by an article that will be p...
Source: Guardian Unlimited Science - November 28, 2013 Category: Science Authors: Kostas Kostarelos Tags: theguardian.com Blogposts Health Medical research Nanotechnology Society Science Source Type: news

Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Data to Be Presented at the 2013 WFNO/SNO Meeting SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/... Biopharmaceuticals, OncologyThreshold Pharmaceuticals, Glioblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 22, 2013 Category: Pharmaceuticals Source Type: news

Anti-Cancer Agent “Avastin" obtained Approval for Additional Indication of Ovarian Cancer in Japan
attached a press release by Chugai (Source: Roche Investor Update)
Source: Roche Investor Update - November 22, 2013 Category: Pharmaceuticals Source Type: news

Bevacizumab May Bring Back Vision in Optic Pathway GliomasBevacizumab May Bring Back Vision in Optic Pathway Gliomas
Bevacizumab treatment of children with optic pathway gliomas (OPG) appears to produce marked recovery of vision, according to a new report of four cases. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 21, 2013 Category: Opthalmology Tags: Hematology-Oncology News Source Type: news

Possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab's blockage of VEGF-A to continue to drive tumor growth. "Think of it like damming a river... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
(University of Colorado Denver) A University of Colorado Cancer Center study published in the journal PLoS One shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab's blockage of VEGF-A to continue to drive tumor growth. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 28, 2013 Category: Global & Universal Source Type: news

Landmark UK-led trial shows Avastin® (bevacizumab) can prolong life in women with advanced ovarian cancer
New data show that Avastin improves overall survival (OS) in women with high risk advanced ovarian cancer - the deadliest gynaecological cancer in the UK2 - offering hope for thousands of women diagnosed with the disease each year.3 Final data have been presented at the European Society of Gynaecological Oncology (ESGO) meeting in Liverpool from the international phase III ICON7 study, led by Leeds-based Dr Timothy Perren, which included 46 trial centres in the UK... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 24, 2013 Category: Consumer Health News Tags: Ovarian Cancer Source Type: news

Bevacizumab Plus Capecitabine Benefits in Elderly mCRCBevacizumab Plus Capecitabine Benefits in Elderly mCRC
Elderly patients with metastatic colorectal cancer (mCRC) benefit from combining bevacizumab with capecitabine. Is this a new standard of care? Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bevacizumab With Low-Dose Interferon-Α2a in Metastatic RCCBevacizumab With Low-Dose Interferon-Α2a in Metastatic RCC
Learn more about the regimen of bevacizumab plus low-dose IFN (3 MIU) as an option for the first-line treatment of patients with clear-cell mRCC. Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Bevacizumab: Mixed Results in Glioblastoma Bevacizumab: Mixed Results in Glioblastoma
Prof. Wolfgang Wick reviews the neuro-oncology highlights from ECC 2013, focusing on glioblastoma and mixed results of bevacizumab trials. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Two-Drug Maintenance May Not Pan Out in NSCLC (CME/CE)
(MedPage Today) -- Combination maintenance therapy with erlotinib (Tarceva) and bevacizumab (Avastin) modestly delayed progression but not death in advanced non-small cell lung cancer, the ATLAS trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 7, 2013 Category: Hematology Source Type: news

Germany's Merck sees long-term growth in cancer drug Erbitux
DARMSTADT, Germany (Reuters) - German healthcare company Merck KGaA expects to get a long-term boost from study results in June that showed its main cancer drug Erbitux has an edge over rival product Avastin. (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

TKI Hikes Survival in Recurrent Ovarian CancerTKI Hikes Survival in Recurrent Ovarian Cancer
Cediranib, bevacizumab, and novel antiangiogenic agents continue to improve survival in first-line and recurrent ovarian cancer, as reported by Dr. Stanley Kaye from ECC 2013. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Erbitux significantly extends survival by 7.5 Months in mCRC RAS wild-type patients when compared with Bevacizumab: New analysis of FIRE-3 AIO study
Merck Serono, the biopharmaceutical division of Merck, has announced that the German cooperative investigator group AIO (Arbeitsgemeinschaft Internistische Onkologie) reported new data from the Phase III head-to-head clinical trial FIRE-3, which show a clinically relevant improvement from Erbitux® (cetuximab) plus FOLFIRI versus bevacizumab plus FOLFIRI as 1st line treatment in metastatic colorectal cancer (mCRC) in patients with RAS wild-type tumors.[1] The new data, from a preplanned exploratory analysis, were presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2013 Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news

New Angiogenesis Inhibitor Succeeds in Gastric Cancer New Angiogenesis Inhibitor Succeeds in Gastric Cancer
A new angiogenesis inhibitor that looks to be a follow-on to bevacizumab has succeeded in gastric cancer trials, but not in breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cancer drug can treat blindness finds HTA funded research
A cheap cancer drug is just as effective and safe in treating a common cause of loss of vision as an expensive alternative, finds research funded by the NIHR Health Technology Assessment (HTA) Programme. The two year study, which published its results in The Lancet, compared anti-cancer drug Avastin (bevacizumab) with Lucentis (ranibizumab), the drug... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - September 26, 2013 Category: American Health Source Type: news

No Toxicity Hit With Avastin in Glioblastoma (CME/CE)
ATLANTA (MedPage Today) -- Progression of glioblastoma slowed significantly without added toxicity when patients received bevacizumab with standard chemoradiation, results of a randomized trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 23, 2013 Category: Hematology Source Type: news

Therapeutic Human Monoclonal Antibodies Against Cancer
There are over 30 monoclonal antibodies that are FDA approved for a variety of diseases ranging from malignancies to autoimmune diseases to macular degeneration. These antibodies include murine, fully humanized, and chimeric antibodies. There are a number of monoclonal antibodies used in the treatment of malignancies; in fact, three of the top five grossing antibodies (bevacizumab, trastuzumab, and rituximab) are used in oncology Scolnik (mAbs 1:179–184, 2009). (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - September 20, 2013 Category: Allergy & Immunology Source Type: news

Is This the Key to Bevacizumab Use in CRC?Is This the Key to Bevacizumab Use in CRC?
Dr. David Kerr reports on a plausible study suggesting a link between MMR-deficient colon tumors and response to bevacizumab in the adjuvant setting. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Second-line pazopanib effective in advanced RCC
Pazopanib demonstrated activity as a second-line treatment in patients with metastatic clear cell renal cell carcinoma who underwent first-line single-agent treatment with sunitinib or bevacizumab, according to results of a phase 2 trial.09/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 12, 2013 Category: Cancer & Oncology Source Type: news

Bevacizumab, Ranibizumab Improve Vision in Choroidal OsteomaBevacizumab, Ranibizumab Improve Vision in Choroidal Osteoma
Intravitreal injections of antivascular endothelial growth-factor agents are effective in the majority of eyes with choroidal neovascularization. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Bevacizumab May Boost Survival in GlioblastomaBevacizumab May Boost Survival in Glioblastoma
Although not conclusive, a new study shows that patients with glioblastoma are surviving longer since bevacizumab was approved for this indication. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Glioblastoma survival improved following FDA approval of bevacizumab
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 21, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - August 19, 2013 Category: Research Authors: Mayo Clinic Source Type: news

Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - August 19, 2013 Category: Hospital Management Authors: Mayo Clinic Source Type: news

Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 19, 2013 Category: Databases & Libraries Authors: Mayo Clinic Source Type: news

Brain cancer survival improved following FDA approval of bevacizumab, Mayo study finds
(Mayo Clinic) A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 19, 2013 Category: Global & Universal Source Type: news

First participant in Midwest enrolls in study of personalized vaccine for brain tumors
(Northwestern Memorial Hospital) Randomized phase II trial will investigate vaccine therapy combined with Avastin for patients with recurrent glioblastoma multiforme. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2013 Category: Global & Universal Source Type: news

Aflibercept for Exudative AMD Aflibercept for Exudative AMD 
How do patients with exudative AMD with persistent fluid on OCT despite receiving regular ranibizumab and/or bevacizumab respond to aflibercept? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Bevacizumab and QoL in Advanced Ovarian CancerBevacizumab and QoL in Advanced Ovarian Cancer
Does quality of life improve for patients with ovarian cancer who are treated with an anti-angiogenesis agent? Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Pemetrexed–bevacizumab effective maintenance therapy for NSCLC
Pemetrexed in combination with bevacizumab is superior to bevacizumab alone when given as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer, results of the AVAPERL trial show. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - July 29, 2013 Category: Cancer & Oncology Source Type: news

Pemetrexed–bevacizumab effective maintenance therapy for NSCLC
Pemetrexed in combination with bevacizumab is superior to bevacizumab alone when given as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer, results of the AVAPERL trial show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 29, 2013 Category: Cancer & Oncology Source Type: news

Modified IFN-Bevacizumab Regimen in Renal CancerModified IFN-Bevacizumab Regimen in Renal Cancer
For first-line treatment of metastatic renal cell carcinoma (mRCC), low-dose interferon-alpha (IFN) works as well as high-dose IFN when combined with bevacizumab and is better tolerated. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

NHS could save £84m using cheaper drug to prevent blindness, trial finds
Researchers say Avastin is just as good as more-expensive Lucentis for treating wet age-related macular degenerationThe NHS could save more than £84m a year if it used a cheap, unlicensed drug to treat people in danger of going blind rather than the expensive one currently licensed and promoted by leading pharmaceutical companies for the purpose, a ground-breaking trial has shown.Researchers led by Prof Usha Chakravarthy from Queen's University Belfast have finally provided an answer to the controversial question of whether the cancer drug Avastin can safely be used to treat people with wet age-related macular degene...
Source: Guardian Unlimited Science - July 19, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian Pharmaceuticals industry News Health Medical research Society UK news Disability Blindness and visual impairment NHS Business Science Source Type: news

Avastin as Good as Lucentis for AMD (CME/CE)
(MedPage Today) -- Bevacizumab (Avastin) appears to have efficacy similar to that of ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration, and monthly administration may offer some advantages over as-needed treatment, randomized trial results showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 19, 2013 Category: Consumer Health News Source Type: news